CrossrefInfokarte
CD39, CD73, and CD38 track tumor burden and reveal immune remodeling during mogamulizumab therapy in Sézary syndrome
Journal for ImmunoTherapy of Cancer · 2026-11 · 14 (11) · e016705
DOI: 10.1136/jitc-2026-016705 ↗Abstract
Kein Abstract verfügbar.
EUVIMED